Merck & Co Inc has taken another step to bolster its immuno-oncology pipeline with the acquisition of privately-owned IOmet Pharma of Scotland and its pre-clinical portfolio of small molecule drugs targeting enzymes involved in a number of cancers. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
